New Research Shows Cannabis Compounds May Boost Liver and Heart Health

Why It Matters

Fatty liver affects roughly one‑third of adults, driving healthcare costs and progression to cirrhosis; effective, low‑risk treatments could curb this epidemic. Demonstrating that CBD and CBG improve key metabolic markers positions cannabis‑derived compounds as promising candidates for MASLD management.

Key Takeaways

• CBD and CBG improve liver energy reserves.
• CBG reduces body fat and LDL cholesterol more.
• Metabolic remodeling boosts phosphocreatine and cathepsin activity.
• Potential plant‑based treatment for MASLD emerges.
• Further human studies required to validate results.

Pulse Analysis

Metabolic dysfunction associated steatotic liver disease (MASLD) now accounts for about 33% of adult liver disorders worldwide, imposing a growing burden on health systems already strained by obesity and diabetes. Conventional management relies on lifestyle modification and, in advanced cases, costly pharmaceuticals with limited efficacy. As patients and clinicians search for safer, more accessible options, attention has turned to botanical compounds, especially cannabinoids, whose anti‑inflammatory and anxiolytic properties have already entered mainstream wellness markets.

The HU School of Pharmacy study adds a mechanistic layer to this interest. By elevating phosphocreatine reserves, CBD and CBG supply the liver with a rapid‑access energy buffer during high‑fat dietary stress, a pathway not typically exploited by the organ. Simultaneously, both cannabinoids reactivate cathepsin enzymes, enhancing lysosomal clearance of toxic lipids such as triglycerides and ceramides. Notably, CBG outperformed CBD in reducing visceral fat, improving insulin sensitivity, and lowering LDL cholesterol, suggesting distinct therapeutic niches within the cannabinoid family. These findings point to a dual‑action model—energy support plus detoxification—that could halt or reverse fatty infiltration before fibrosis sets in.

Translating these preclinical insights into clinical practice will require rigorous human trials, standardized dosing, and navigation of regulatory frameworks that still treat many cannabinoids as controlled substances. If validated, the market potential is sizable: a plant‑based, non‑psychoactive therapy could capture a share of the multi‑billion‑dollar NAFLD treatment space while offering patients a low‑risk adjunct to diet and exercise. Investors and biotech firms are likely to monitor this space closely, as the convergence of metabolic health and cannabis research promises both health benefits and commercial opportunity.